It's nominations time again!

Don't miss your chance to nominate your star of the rare disease community, or enter yourself, for one of the EURORDIS Black Pearl Awards 2022.

 

Following the many requests we have received, the deadline to submit a nomination has been postponed to this Friday, 17th September (18:00 CET).

 

The 12 award categories recognise the outstanding efforts of individuals, organisations, companies, researchers, scientists, media, and policy makers in bringing about change to improve the lives of the 30 million people in Europe and 300 million worldwide living with a rare disease.

Nominations can be submitted from anywhere in the world!

 

Among all the nominations received, the EURORDIS Board of Directors will select the awardees in October 2021. EURORDIS has partnered with Orphanet for the evaluation of the Scientific Award nominations and with Medtech Europe for the Company Award for Health Technology.

 

A few finalists will be selected for the Young Patient Advocate Award and the Social Media Award, for which the winners will be determined by a public vote. 

 

The awardees will be presented with their awards at the official Ceremony next February, to mark the occasion of Rare Disease Day. 

Read more about the categories below and click to make your nomination in just a few minutes.

 

See our previous awardees for inspiration.
Any questions regarding the nomination process? Do not hesitate to contact Martina Bergna, EURORDIS Events Manager, at martina.bergna@eurordis.org.

 

 

 

Categories and criteria

Learn more about the award categories and nomination criteria by clicking on the titles below.

Lifetime Achievement Award
For an individual who has manifested a lifelong dedication to addressing the needs of people living with a rare disease. Their commitment has had a positive impact on the rare disease community at large, wielding influence on a European or international scale.
The winner is selected on the basis of the following criteria:

  • Their collaborative approach to advancing the cause of all rare diseases
  • Their role in representing patient voices on a national, European, or international scale
  • Their influence on patient-centred rare disease health policy and legislation
  • Their leadership and drive for positive change in the field of rare diseases
  • Their involvement in national and European/international committees and advisory groups

Young Patient Advocate Award
For a young, outstanding individual (of age 30 or under) who actively contributes to raising awareness of key issues for people living with a rare disease at a local, national, or international level. The award recognises dedication and commitment to positively impacting the community by educating a wider audience consisting of decision makers, the public, and/or the media.

 

European Rare Disease Leadership Award
For an individual who has shown remarkable leadership in the field of rare diseases at a European level. Awardees advocate for rare diseases and beneficially impact the community by educating decision makers, the public, and the media and/or by affecting policy and legislation to achieve positive change through effective advocacy at the local, national and/or international levels.

 

Policy Maker Award
For a policy maker whose dedication and commitment has made a significant difference to the rare disease community. The award recognises an outstanding individual who has demonstrated excellence in championing the rare disease cause at a local, national, and international level. The award commends a commitment to advancing the implementation of policies to improve the life of people with rare diseases, fostering funding programmes to support research and development, and raising awareness of key issues of relevance to our community.

 

Scientific Award

In collaboration with Orphanet (https://www.orpha.net/).

For a distinguished researcher whose career represents a rare combination of scientific excellence and support for the patient community.

The winner is selected on the basis of the following criteria:

  • Whether the researcher has initiated and nurtured international/European collaboration(s) leading to a significant improvement in the understanding of the pathogenic mechanisms or therapeutic development of rare diseases
  • Whether the researcher has engaged with rare disease patients in their work, e.g. through the involvement of patients in study design, prioritisation of research topics, and/or selection of patient-centred outcomes
  • Whether the researcher’s work has significantly contributed to a scientific breakthrough in a specific rare disease
  • Whether the researcher raises awareness of a given disease or other non-product related projects within the community

 

 

 

 

 

 

 

 

EURORDIS Volunteer Awards
Up to two EURORDIS Volunteer Awards will be presented in 2022 to individuals who have made an outstanding contribution to EURORDIS and the rare disease community on a voluntary basis.

 

EURORDIS Members Award
For a EURORDIS member patient organisation demonstrating innovative methods in patient support or advocacy.

 

Media Award

For an individual or group creating a media piece to raise awareness of rare diseases and bring the needs of people living with a rare disease to a wider audience. The award promotes excellence in journalism, photography, cinema, series, art, literature, and mass media.

Social Media Award
Established in 2022, the Award is presented to an individual or organisation who have created innovative and meaningful social media content, advocating for people with rare diseases and bringing the reality of their daily lives into the public arena.

Communication, awareness raising, creativity and ability to reach people outside the rare disease community are the qualities we value most. The Award honours the best advocates on social media platforms such as Twitter, Facebook, YouTube, Instagram, and TikTok.

Company Award for Innovation

For a pioneering company using innovative methods to develop treatments for rare diseases.

The winner is selected on the basis of the following criteria:

  • Is the company developing treatments that address unmet medical needs?
  • Does the company work in therapeutic areas with small patient populations and in which there is currently no treatment available?
  • Are the company's treatments based on new, promising research or technology?
  • Does the company build partnerships with other stakeholders (i.e. academia/universities, entrepreneurs, clinicians) to explore research/therapies that could be applied to rare diseases?
  • Has the company's engagement with patients led to more relevant trial designs or safer and more adequate treatments?
  • Does the company's business model enable the acceleration of advances in rare disease therapies?
  • Does the company facilitate access to its treatments for all rare disease patients?

 

Company Award for Patient Engagement

For a company that demonstrates long-term commitment in its collaboration with rare disease patients, consulting with them in the early stages of development and clinical trial design.

The winner is selected on the basis of the following criteria:

  • Does the company collaborate with rare disease patients from the early stages of development and throughout the entire product life cycle?
  • Has the company signed the EURORDIS Charter or established a CAB / any other form of patient advisory group?
  • Can the company prove how patient engagement has led to improved endpoints, patient outcomes, or dossiers for regulatory evaluation?
  • Does the company raise awareness of a given disease or other non-product related projects within its community?
  • Does the company ensure patient safety and transparency on pricing?
  • Does the company have a compassionate use/expanded access programme?

 

Company Award for Health Technology

In collaboration with Medtech Europe (https://www.medtecheurope.org/).

For any company working in the field of technology developing medical devices, IT platforms, health apps, or diagnostic tools aiming to improve the lives of people living with a rare disease.

The winner is selected on the basis of the following criteria:

  • The positive impact on the daily lives of patients and their carers
  • The extent to which the technology enables a quicker/more accurate diagnosis
  • The extent to which the technology helps better to identify or design the final outcomes for patients
  • The extent to which the technology generates more valuable data and enables the collection of real-world evidence
  • The extent to which the technology allows more patients to be reached, especially those who live in areas where there is little to no infrastructure for rare diseases

 

 

 

 

 

 

Previous Recipients

Find out all about the individuals, organisations and companies who dedicate their lives to making a difference for the rare disease community.